Antibody Drug Conjugates Market Size Worth US$ 18.5 Billion Globally by 2027, at 23.8% CAGR

According to the latest report by IMARC Group, titled "Antibody Drug Conjugates Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027," the global antibody drug conjugates market size reached a value of US$ 5.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 18.5 Billion by 2027, exhibiting at a CAGR of 23.8% during 2022-2027.

Antibody drug conjugates (ADCs) refer to highly potent biological drugs consisting of tumor-targeting antibodies, which are chemically bound to a cytotoxic effector molecule. They deliver anticancer agents to affected cells by connecting them to monoclonal antibodies (mAb) via biodegradable linkers and allowing sensitive bifurcation between diseased and healthy tissues. ACDs assist in enhancing drug tolerability, increasing the cell-killing potential of mAb, and limiting systematic exposure compared to standard chemotherapy bioactive compounds. As a result, these drugs find widespread applications across hospitals, specialized cancer centers, academic research institutes, biotechnology companies, etc.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Request Free Sample Report (Exclusive Offer on this report): https://www.imarcgroup.com/antibody-drug-conjugates-market/requestsample

Antibody Drug Conjugates Market Trends:

The rising number of individuals smoking and drinking regularly, and the sedentary lifestyles are among the primary factors driving the antibody drug conjugates market. Besides this, the escalating demand for cost-effective and successful cancer treatments across the globe is further augmenting the market growth. Moreover, the extensive research and development (R&D) activities by the leading players to manufacture novel chemical triggers for generating stable and homogenous ADCs are also catalyzing the global market. Apart from this, the launch of additional linkers to allow the expansion of payloads and reduce off-target toxicity is acting as another significant growth-inducing factor. Furthermore, the expanding healthcare infrastructure, increasing awareness among the masses towards the therapies available for cancer treatments, and the introduction of cleavable technology are expected to bolster the antibody drug conjugates market in the coming years.

Competitive Landscape with Key Players:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market:

• ADC Therapeutics SA
• Astellas Pharma Inc.
• AstraZeneca plc
• Celldex Therapeutics Inc.
• Hoffmann-La Roche AG
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• ImmunoGen Inc
• Pfizer Inc.
• Sanofi S.A.
• Seagen Inc.
• Sorrento Therapeutics Inc.
• Takeda Pharmaceutical Company Ltd.

Ask Analyst for Instant Discount and Download Full Report with TOC & List of Figure: https://www.imarcgroup.com/antibody-drug-conjugates-market

Key Segmentation:

Breakup by Component:

• Monoclonal Antibodies
• Linker
• Cytotoxic Agent
• Others

Breakup by Target:

• Antibody-Protein Toxin Conjugates
• Antibody-Chelated Radionuclide Conjugates
• Antibody-Small-Molecule Drug Conjugates
• Antibody-Enzyme Conjugates

Breakup by Application:

• Lymphoma
• Ovarian Cancer
• Lung Cancer
• Breast Cancer
• Brain Tumor
• Others

Breakup by End User:

• Hospitals
• Specialized Cancer Centers
• Academic Research Institutes
• Biotechnology Companies
• Others

Breakup by Region:

• Middle East and Africa
• North America
• Asia-Pacific
• Europe
• Latin America

Key highlights of the Report:

• Market Performance
• Market Outlook
• Porter's Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Contact Us:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.